AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

AbbVie Inc. (NYSE:ABBV) is one of the top S&P 500 stocks by index weight. On April 13, AbbVie Inc. (NYSE:ABBV) entered into an exclusive licensing agreement with Haisco Pharmaceutical Group for the development of pain medicines.

AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

Photo by Pietro Jeng on Pexels

Under the terms of the agreement, AbbVie will own the rights to develop, manufacture, and commercialize novel pain treatment compounds globally, excluding China, Hong Kong, and Macau. The program aims to cover multiple compounds that can address various pain-related indications.

The compounds are currently under development in various stages in China. They include Nav1.8 inhibitors that block pain signals at the source. The compound spans preclinical through Phase I development in China and is positioned for chronic pain indications.

In return, Haisco is to receive $30 million in upfront payment and is also eligible for an additional $715 million in aggregate development, regulatory, and commercial milestone payments. Haisco is also entitled to tiered royalties on future net sales emanating from the compounds under development.

AbbVie Inc. (NYSE:ABBV) is a global research-driven biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for complex and serious health conditions. They specialize in immunology, oncology, neuroscience, eye care, and aesthetics, aiming to improve patient care standards.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Defense Stocks That Will Skyrocket and Top 10 Utility Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.